Regenacy Pharmaceuticals, Inc. Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

Regenacy Pharmaceuticals, Inc. is a biotechnology research company focused on developing disease-modifying therapies for peripheral neuropathies, aiming to restore nerve function rather than merely alleviate pain. Its lead candidate, ricolinostat (ACY-1215), is an oral inhibitor targeting HDAC6, with a development path that includes plans for Phase 2 trials in conditions such as diabetic and chemotherapy-induced neuropathies, as well as inherited neuropathies. The firm also maintains a portfolio of selective HDAC1/2 inhibitors with potential applications across cancer, blood disorders, and cognitive dysfunction.

Based in Waltham, Massachusetts, Regenacy was established in 2016 after the acquisition of Acetylon Pharmaceuticals and subsequently gained exclusive rights to ricolinostat for non-cancer indications. A notable recent development includes a joint venture established in 2020 with 3E Bioventures to advance ricolinostat for peripheral neuropathies, including a plan for a US-based Phase 2 study following a China collaboration.

Get verified Regenacy Pharmaceuticals, Inc. emails free

Company overview Employee directory